

Educational webinar:

The
George
Institute
for Global Health

Better treatments
Better care
Healthier societies

Overcoming barriers to wider SGLT2 inhibitor use

Wednesday 9th March 2022, 6pm – 7pm AEDT

Strong evidence exists to demonstrate the benefit of SGLT2 inhibitor use for indications beyond diabetes management, including kidney disease and heart failure, however the uptake to use SGLT2 inhibitors more widely has been slow. This educational webinar seeks to improve understanding of the evidence and demonstrate how SGLT2 inhibitors can be used using a range of examples, based on your input about what current knowledge gaps are.

In the registration you can provide your areas of interest/concern in order for us to tailor the webinar content accordingly. We will present identified areas of interest as patient cases to enable more comprehensive understanding of application.

Date and Time: Wednesday 9th March 2022, 6pm – 7pm AEDT

Speakers:

Prof Hiddo Heerspink
DAPA-CKD Trial Steering
Committee Co-Chair



Prof Vlado Perkovic
CRENCE Trial Steering
Committee Chair and Member



Dr Clare Arnott
Cardiologist and
Head of Heart failure Program
at The George Institute



Dr Brendon Neuen
Postgraduate Scholar
The George Institute
for Global Health



To register please click here: www.bit.ly/3IQ4FhT

This webinar has received support from AstraZeneca by way of an unconditional educational grant. The George Institute has complete control of the scientific content for this educational webinar, without external input or influence. We maintain confidentiality of all audience information.

As a not for profit organisation we seek sponsorship where possible and appropriate to support our ongoing work. Any such funds go towards to achieving our mission of improving the health of millions of people worldwide.